ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic drugs"

  • Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting

    Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

    René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
  • Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting

    Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients

    Jean-Guillaume Letarouilly1, Benoit Flachaire 2, Céline Labadie 3, Jérémie Sellam 4, Pascal Richette 5, Philippe Dieudé 6, Pascal Claudepierre 7, Bruno Fautrel 8, Eric Houvenagel 9, Chi Duc Nguyen 10, Marie-Hélène Guyot 11, Nicolas Segaud 12, Frédéric Maury 13, Laurent Marguerie 14, Xavier Deprez 15, Jean-Hugues Salmon 16, Guy Baudens 17, Elisabeth Gervais 18, Isabelle Chary-Valckenaere 19, Pierre Lafforgue 20, Damien Loeuille 21, Christophe Richez 22, Thao Pham 20 and René-Marc Flipo 23, 1University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, 2Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, 3Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, 4Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, 5Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, 6Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, 7Rheumatology, CHU Henri Mondor Créteil, Paris, France, 8Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 9Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, 10Rheumatology, Hospital of Béthune, Béthune, Béthune, France, 11Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, 12Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, 13Rheumatology, Private Practice, Beuvry, Beuvry, France, 14Rheumatology, Calot Institute, Berck, Berck-sur-Mer, 15Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, 16Rheumatology, Reims University Hospital, Reims, Reims, France, 17Rheumatology, Private Practice, Valenciennes, Valenciennes, France, 18CHU de Poitiers, Rheumatology, Poitiers, France, 19Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 20Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 21Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, 22Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, 23University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France

    Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…
  • Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting

    The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry

    Sadettin Uslu1, Gercek Can 2, Ayşe Cefle 3, Sema Yılmaz 4, Sinem Burcu Kocaer 5, Tuba Yüce İnel 1, Semih Gülle 1, Süleyman Serdar Koca 6, Servet Yolbaş 7, Mehmet Akif Öztürk 8, Soner Senel 9, Nevsun Inanc 10, Ediz Dalkılıç 11, Ozgül Gunduz 12, Abdurrahman Tufan 8, Servet Akar 13, Merih Birlik 5, Ismail Sari 1, Nurullah Akkoç 12 and Fatos Onen 14, 1Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, 2Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, 3Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, 4Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, 5Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, 6Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, 7Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, 8Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, 9Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, 10Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 11Uludağ University, Bursa, Turkey, 12Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, 13Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey

    Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
  • Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting

    Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib

    Evelyne Vinet1, Yvan St-Pierre 1, Cristiano S. Moura 1, Jeffrey Curtis 2 and Sasha Bernatsky 3, 1McGill University Health Centre, Montreal, QC, Canada, 2University of Alabama at Birmingham, Birmingham, AL, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
  • Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting

    Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies

    Alexander Peck1, Ella Starobinska 2, Gilbert Ortega 1, Travis Maestas 1, Jaclyn Leong 1, Phan Saligrama 1, Jawad Bilal 1 and Dominick Sudano 3, 1University of Arizona College of Medicine, Tucson, AZ, 2University of Arizona College of Medicine, Tucson, AL, 3Banner University Medical Center Tucson, Tucson

    Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
  • Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting

    Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up

    Sebastian C Rodriguez-Garcia1, Raul Castellanos-Moreira Sr.1, José Inciarte-Mundo2, M. Victoria Hernández3, Virginia Ruiz-Esquide2, Andrea Cuervo1, Julio Ramírez2, Juan Cañete1, Jose Gomez Puerta1 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain

    Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
  • Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting

    Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety

    Jeffrey R. Curtis1, Gregory St. John2, Michael Pannucci2, Yong Lin3, José A. Maldonado-Cocco4, Tom W.J. Huizinga5, Marina Stanislav6 and Paul Emery7, 1University of Alabama, Birmingham, AL, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Universidad de Buenos Aires, Buenos Aires, Argentina, 5Leiden University Medical Center, Leiden, Netherlands, 6Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
  • Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting

    Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System

    Sarah L. Patterson1, Michael Evans2, Ishita Aggarwal3, Zara Izadi4, Milena Gianfrancesco5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California - San Francisco, San Francisco, CA, 3Medicine, Santa Clara Valley Medical Center, San Jose, CA, 4Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 5Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6San Francisco VA Medical Center, San Francisco, CA, 7University of California, San Francisco, San Francisco, CA

    Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
  • Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting

    The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis

    Maria A. Lopez-Olivo1, Aliza Matusevich2, Scott B. Cantor3, Gregory Pratt4 and Maria Suarez-Almazor5, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 3Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 5Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX

    Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
  • Abstract Number: 2044 • 2018 ACR/ARHP Annual Meeting

    Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies

    Ivan Arias de la Rosa1, Patricia Ruiz-Limon1, Carlos Perez-Sanchez2, Maria Carmen Abalos-Aguilera1, Yolanda Jiménez-Gómez2, Irene Cecchi3, Rafaela Ortega-Castro2, Miguel Angel Caracuel-Ruiz4, Jerusalem Calvo-Gutierrez2, Alejandro Escudero-Contreras1, Eduardo Collantes-Estévez2, Chary Lopez-Pedrera4 and Nuria Barbarroja2, 1Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain

    Background/Purpose: Neutrophils are the most abundant cells in synovial fluid, having all the features of activated cells in rheumatoid arthritis (RA), including prolonged cell survival,…
  • Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting

    The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

    Dimitrios A. Pappas1, Gregory St. John2, Carol J. Etzel1, Stefano Fiore3, Taylor Blachley1, Toshio Kimura2, Rajeshwari Punekar3, Kelechi Emeanuru4, Susan Boklage2 and Joel Kremer1,5, 1Corrona LLC, Waltham, MA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi, Bridgewater, NJ, 4Corrona, LLC, Waltham, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
  • Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting

    Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis

    Burcu Yagız1, Belkıs Nihan Coşkun2, Sedat Kiraz3, Ihsan Ertenli4, Orhan Kucuksahin5, Ediz Dalkiliç6, Cemal Bes7, Nilufer Alpay Kanitez8, Timucin Kasifoglu9, Hakan Emmungil10, Pamir Atagunduz11, Suleyman Serdar Koca12, Muhammet Cinar13, Aşkın Ateş14, Servet Akar15, Onay Gercik16, Duygu Ersozlu Bakirli17, Veli Yazisiz18, Gezmis Kimyon19, Nazife Sule Yasar Bilge20, Muge Aydin Tufan21, Ridvan Mercan22, Burak Oz12, Zeynel Abidin Akar12, Omer Karadag23, Bahar Kelesoglu24, Sedat Yılmaz25, Sezin Turan26, Yavuz Pehlivan2, Ender Terzioglu27, Levent Kilic23, Sukran Erten28, Koray Tascilar29 and Umut Kalyoncu30, 1Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 2Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 3Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 4Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 5Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, 6Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, 7Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 8Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, 9Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 10Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, 11Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 12Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 13Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, 14Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, 15Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, 16Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 17PsART study group, Adana, Turkey, 18Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 19Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, 20Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 21Rheumatology, Cukurova University School of Medicine, Adana, Turkey, 22Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 23Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 24Rheumatology, Ankara University, Ankara, Turkey, 25Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, 26Trakya University Medical Faculty, Edirne, Turkey, 27Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 28PsART study group, Ankara, Turkey, 29Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey, 30Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…
  • Abstract Number: 2078 • 2018 ACR/ARHP Annual Meeting

    Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy

    Patricia Ruiz-Limon1, M. Carmen Castro-Villegas2, Chary Lopez-Pedrera3, Rafaela Ortega-Castro4, Maria Carmen Abalos-Aguilera1, Nuria Barbarroja4, Carlos Perez-Sanchez4, Ivan Arias de la Rosa1, Alejandro Ibáñez-Costa3, Alejandra Maria Patiño-Trives3, Daniel Espejo-Peralbo1, Pilar Font-Ugalde4, Jose Antonio Gonzalez-Reyes5, Jose Manuel Villalba5, Clementina López-Medina4, Alejandro Escudero-Contreras1, Eduardo Collantes-Estévez4 and Yolanda Jiménez-Gómez4, 1Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain

    Background/Purpose: NETosis has been suggested to play a central role in several rheumatology diseases. Nevertheless, this process, and its modulation in therapeutic response has not…
  • Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting

    TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis

    Daeria O. Lawson1,2, Maria Eraso3, Lawrence Mbuagbaw4, Theresa Aves5, Alvin Leenus4, Marianinha Joanes6, Ahmed Omar1,7 and Robert D Inman8,9, 1Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 2Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, 3Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, 4McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, 5St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 6Boston University School of Medicine, Boston, MA, United States, Boston, MA, 7Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 8Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 9University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
  • Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting

    Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study

    Magali Pacanowski Fournier1, Antoine Brezin2, Christophe Chiquet Sr.3, David Saadoun4, Jeremie Sellam5, Patrice Cacoub6, Pascal Sève7, Bahram Bodaghi Sr.8 and Laurent Kodjikian Sr.9,10,11, 1medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, 2Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, 3ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, 4Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, 5AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, 6Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, 7Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 8ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, 9ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, 10université Claude Bernard lyon 1, villeurbanne, France, 11UMR-CNRS 5510 Matéis, villeurbanne, France

    Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology